DUBLIN–(BUSINESS WIRE)–The “Cell Culture Media Market by Type (Serum-free (CHO, BHK, Vero Cell), Stem Cell, Chemically Defined, Classical, Specialty), Application (Biopharmaceutical (mAbs, Vaccine), Diagnostics, Tissue Engineering), End User (Pharma, Biotech) – Global Forecast to 2026” report has been added to ResearchAndMarkets.com’s offering.
The global cell culture media market is projected to USD 10.3 billion by 2026 from USD 4.9 billion in 2021, at a CAGR of 16.0 % between 2021 and 2026.
The growth of this market is majorly driven by the growing awareness about the benefits of cell-based vaccines, increasing demand for monoclonal antibodies (mAbs), funding for cell-based research, growth in stem cell research, the launch of new cell culture media by market players, and the growing focus on personalized medicine. On the other hand, the high cost of cell biology research is restraining the growth of this market.
The serum-free media segment accounted for the highest growth rate in the cell culture media market, by type, during the forecast period
In 2020, the serum-free media segment accounted for the largest share of the market. This can be attributed to the advantages of serum-free media over other types of media, including consistent performance, increased growth & productivity, better control over physiological responsiveness, and reduced risk of contamination by serum-borne adventitious agents in cell culture.
Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Danaher Corporation (US), Sartorius AG (Germany), Corning Incorporated (US), FUJIFILM Irvine Scientific, Inc. (Japan), Lonza Group AG (Switzerland), Becton, Dickinson and Company (US), MiltenyiBiotec (Germany), HiMedia Laboratories Pvt. Ltd. (India), STEMCELL Technologies Inc. (Canada), Biologos LLC (US), Cell Applications, Inc. (US) are some of the major players operating in the cell culture media market.
Asia Pacific: The fastest-growing region in the cell culture media market
The cell culture media market is segmented into North America, Europe, Asia Pacific, Latin America (LATAM) and Middle East and Africa (MEA). The Asia Pacific market is expected to register the highest CAGR of 17.5% during the forecast period. The growing geriatric population, favorable regulatory guidelines, government support for cell culture-based vaccine production, low manufacturing costs, and the growing focus of global market players on emerging Asian economies are the major factors contributing to the growth of the cell culture media market in Asia Pacific.
Market Dynamics
Drivers
- Rising R&D Spending in Pharmaceutical Companies
- Emerging Cell Culture Technologies for Cell-Based Vaccines
- Increasing Demand for Monoclonal Antibodies
- Growth in Stem Cell Research
- Launch of New Cell Culture Media Products by Market Players
- Growing Focus on Personalized Medicine
Restraints
- Expensive Cell Biology Research Products
- Ethical Concerns Regarding Cell Biology Research
Opportunities
- Advancements in 3D Cell Culture
- Increasing Incidence of Infectious Diseases and Outbreaks of Pandemics
- Emerging Markets
Challenges
- Survival of Small Players and New Entrants
Companies Mentioned
- Akron Biotech
- Athena Environmental Sciences, Inc.
- Becton, Dickinson and Company (BD)
- Biologos LLC.
- Biowest Sas
- Caisson Laboratories Inc.
- Cell Applications, Inc.
- Cell Biologics, Inc.
- Cellular Technology Limited LLC.
- Corning Incorporated
- Cyagen Biosciences
- Danaher Corporation
- Fujifilm Irvine Scientific, Inc. (Acquired by Fujifilm Holdings Corporation)
- Himedia Laboratories Pvt. Ltd.
- Invivogen
- Lonza Group Ag
- Merck KGaA
- Miltenyi Biotec
- Pan-Biotech GmbH
- Peprotech, Inc.
- Promocell GmbH
- Sartorius AG
- Stemcell Technologies Inc.
- Thermo Fisher Scientific, Inc.
- Zen-Bio, Inc.
For more information about this report visit https://www.researchandmarkets.com/r/pkrovy
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900